A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A

Launched by ADDPHARMA INC. · Mar 31, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to compare two medications, AD-120 and AD-120A, to see how they work in the body and how safe they are for treating gastroesophageal reflux disease (GERD). The study will involve healthy volunteers aged between 19 and 50 years who weigh between 50 to 90 kilograms and have a healthy body mass index. Participants will need to have a negative test for a specific stomach bacteria called Helicobacter pylori before joining the trial.

The trial is currently not recruiting participants, but when it does, those who qualify will receive the medications and be closely monitored to understand how their bodies respond to each one. This is important because it helps researchers determine the best treatment options for people suffering from GERD. If you or someone you know fits the eligibility criteria and is interested in participating, it could be a valuable opportunity to contribute to medical research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Body weight equal to or greater than 50.0kg and equal to or less than 90.0kg and Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening visit
• • The Age equal to or greater than 19 and equal to or less than 50 in healthy volunteers at the time of screening visit
• • Negative result from Serum Helicobacter pylori antibody at the time of screening visit
• Exclusion Criteria:
• • Patients with trouble performing pH monitor catheter